AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress
二重特異性抗体エポリタマブ(DuoBody-CD3xCD20)の再発/難治性大細胞型B細胞リンパ腫(LBCL)患者を対象とした第2相試験の最新成績を欧州血液学会(EHA)年次総会でAbbVieが発表
